The invention relates to murine monoclonal antibodies (MAbs), A, B, C and D,
which are directed against tumor-associated antigens. The nearly complete nucleotide
sequences of the V genes of these MAbs are described, so that the relevant variable
domains can be put together to give chimeric MAbs, or "humanized" MAbs are obtained
by inserting the hypervariable regions (complementarity determining regions=CDR)
into a human MAb framework. Antibody constructs of this type can be employed in
human therapy and in vivo diagnosis without the disadvantages observed with murine MAbs.
